Form 4: Alnylam Pharmaceuticals Executive VP Tolga Tanguler Reports Stock Transactions
SEC Form 4
Tolga Tanguler, Executive VP and Chief Commercial Officer of Alnylam Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
Summary
- On February 27, 2024, Tolga Tanguler, EVP and Chief Commercial Officer of Alnylam Pharmaceuticals, had 1,667 restricted stock units vest.
- These units converted into common stock.
- Simultaneously, 1,667 shares were sold at $0.0 to cover tax obligations.
- From February 28, 2024, Tanguler sold a total of 501 shares of common stock in multiple transactions at weighted average prices ranging from $154.54 to $158.09.
- Following these transactions, Tanguler directly owns 5,236 shares of Alnylam common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions. It doesn't convey any particularly positive or negative sentiment.
Industry Context
Executive stock transactions are a normal part of corporate governance and compensation practices. The sale of shares to cover tax obligations upon vesting of restricted stock units is a common occurrence.
Key Dates
| Date | Description |
|---|---|
| 02/27/2023 | Reporting person was granted 5,000 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. |
| 02/27/2024 | 1,667 restricted stock units vested and were released. |
| 02/28/2024 | Shares of common stock were sold in multiple transactions. |
| 02/29/2024 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.